Universitätspublikationen
Refine
Year of publication
- 2020 (2511) (remove)
Document Type
- Article (1453)
- Doctoral Thesis (233)
- Part of Periodical (215)
- Preprint (169)
- Contribution to a Periodical (140)
- Working Paper (115)
- Book (88)
- Review (58)
- Bachelor Thesis (11)
- Master's Thesis (11)
Language
- English (1715)
- German (764)
- Portuguese (11)
- French (6)
- Spanish (4)
- Italian (3)
- Multiple languages (3)
- slo (3)
- Turkish (2)
Keywords
- Capital Markets Union (25)
- Financial Markets (25)
- Coronavirus (24)
- ECB (24)
- COVID-19 (23)
- inflammation (18)
- SARS-CoV-2 (15)
- coronavirus (15)
- Financial Institutions (13)
- Banking Regulation (12)
Institute
- Medizin (742)
- Präsidium (278)
- Physik (264)
- Wirtschaftswissenschaften (213)
- Sustainable Architecture for Finance in Europe (SAFE) (167)
- Biowissenschaften (159)
- Frankfurt Institute for Advanced Studies (FIAS) (149)
- Informatik (116)
- Biochemie, Chemie und Pharmazie (104)
- Neuere Philologien (95)
- Gesellschaftswissenschaften (94)
- Center for Financial Studies (CFS) (81)
- Rechtswissenschaft (73)
- House of Finance (HoF) (66)
- Psychologie (51)
- Biochemie und Chemie (50)
- Kulturwissenschaften (46)
- Geowissenschaften (44)
- Sprach- und Kulturwissenschaften (38)
- Geschichtswissenschaften (37)
- Senckenbergische Naturforschende Gesellschaft (37)
- Informatik und Mathematik (32)
- Institut für Ökologie, Evolution und Diversität (31)
- Psychologie und Sportwissenschaften (31)
- Erziehungswissenschaften (30)
- Philosophie (29)
- Sportwissenschaften (29)
- Evangelische Theologie (27)
- Geowissenschaften / Geographie (27)
- Institut für Sozialforschung (IFS) (23)
- Biodiversität und Klima Forschungszentrum (BiK-F) (22)
- MPI für Hirnforschung (20)
- Exzellenzcluster Die Herausbildung normativer Ordnungen (19)
- Universitätsbibliothek (19)
- Institut für Wirtschaft, Arbeit, und Kultur (IWAK) (16)
- Deutsches Institut für Internationale Pädagogische Forschung (DIPF) (15)
- Philosophie und Geschichtswissenschaften (14)
- Zentrum für Biomolekulare Magnetische Resonanz (BMRZ) (13)
- Buchmann Institut für Molekulare Lebenswissenschaften (BMLS) (12)
- Foundation of Law and Finance (12)
- E-Finance Lab e.V. (11)
- Ernst Strüngmann Institut (11)
- Institute for Monetary and Financial Stability (IMFS) (11)
- MPI für Biophysik (11)
- Geographie (10)
- Institut für sozial-ökologische Forschung (ISOE) (9)
- Zentrum für Arzneimittelforschung, Entwicklung und Sicherheit (ZAFES) (8)
- Cornelia Goethe Centrum für Frauenstudien und die Erforschung der Geschlechterverhältnisse (CGC) (7)
- Mathematik (7)
- Exzellenzcluster Makromolekulare Komplexe (6)
- Georg-Speyer-Haus (6)
- ELEMENTS (5)
- Pharmazie (4)
- Sprachwissenschaften (4)
- Akademie für Bildungsforschung und Lehrerbildung (bisher: Zentrum für Lehrerbildung und Schul- und Unterrichtsforschung) (3)
- Hochschulrechenzentrum (3)
- MPI für empirische Ästhetik (3)
- Zentrum für Nordamerika-Forschung (ZENAF) (3)
- Forschungszentrum Historische Geisteswissenschaften (FHG) (2)
- Helmholtz International Center for FAIR (2)
- Interdisziplinäres Zentrum für Ostasienstudien (IZO) (2)
- Extern (1)
- Frankfurt MathFinance Institute (FMFI) (1)
- Fritz Bauer Institut (1)
- Gleichstellungsbüro (1)
- Hessische Stiftung für Friedens- und Konfliktforschung (HSFK) (1)
- Institut für Bienenkunde (1)
- Institute for Law and Finance (ILF) (1)
- Interdisziplinäres Zentrum für Neurowissenschaften Frankfurt (IZNF) (1)
- Katholische Theologie (1)
- Museum Giersch der Goethe Universität (1)
- Starker Start ins Studium: Qualitätspakt Lehre (1)
- Zentrum für Interdisziplinäre Afrikaforschung (ZIAF) (1)
- studiumdigitale (1)
Der Erforschung der Bronzestatuetten der Frühen Neuzeit im 19. Jahrhundert wurde bisher wenig Beachtung geschenkt. Die erste umfassende stilkritische Gattungsmonographie mit dem Titel „Die Italienischen Bronzestatuetten der Renaissance“ wurde von Wilhelm von Bode (1845 - 1929) verfasst. Er veröffentlichte diese kurz nach der Eröffnung des neu gebauten Kaiser-Friedrich-Museums in Berlin 1904. Maßgeblich durch Bode geprägt, zeigte dieses Museum erstmals Bronzestatuetten der Renaissance und des Barock als eine eigenständige Skulpturengattung. Die wissenschaftshistorische Frage nach der Entstehung der stilkritischen Kleinbronzenforschung zwischen 1871 und 1904 steht daher im Kontext der Berliner Museums- und Sammlungsgeschichte, mit dem Schwerpunkt auf der Erwerbung der Kleinbronzen, deren Zuschreibung und Präsentation. Ein 1883 veröffentlichtes Konzept für ein Berliner „Renaissancemuseum“ verknüpfte mit der Sammlungspräsentation die Erwartung, der ästhetischen Selbstvergewisserung ihrer Betrachter zu dienen. Die Kunst der Renaissance, darunter auch die Bronzestatuetten, war dabei Sinnbild des modernen bürgerlichen Autonomiebestrebens. Diesem Leitbild stand die Arbeitsorganisation ihres Erforschers Wilhelm von Bode gegenüber, die seine historische Theorie und stilkritische Methode prägte. Neben dem Einfluss Jakob Burckharts und dessen „Kunstgeschichte nach Aufgaben“ geben Bodes Briefwechsel mit Theodor von Frimmel, Louis Courajod und dem Sammler Fürst Johann II. von und zu Liechtenstein Aufschluss über sein Forschungsinteresse. So fokussierte er seine Forschung auf die Statuetten des Bildhauers und Bronzemodelleurs Bertoldo di Giovannis. Hier lässt sich der Wandel von einer kulturgeschichtlichen Perspektive hin zu einer historisch-kritischen Analyse der Statuetten verfolgen. Mit der Transformation der so genannten „Kopienkritik“ aus der klassischen Archäologie und mit Hilfe der Fotografie entwickelte Wilhelm von Bode eine Methode für die stilkritische Analyse der kleinformatigen Skulpturen.
Six dentin adhesives were tested in vitro regarding their cytotoxicity on human fibroblasts. The adhesives Hybrid Bond, One-up Bond F Plus, AdheSE, Clearfil SE Bond, Optibond Solo Plus and Syntac were eluted with culture medium as single or sequentially applied adhesive part for 24 h. 75 Petri dishes were produced per group. They were evaluated triangulated, comprising the quantitative evaluation (105 ones) to determine “viable”, “dead” and “debris” cells with the use of a cell-counter and the reactivity index was also identified based on the qualitative assessment (420 ones). One-up Bond F Plus, AdheSE and Clearfil SE Bond showed a statistical difference of viable cells to the cell control. For One-up Bond F Plus, statistically, differences compared to hybrid bond and Syntac were also found. All the adhesives except One-up Bond F Plus showed significant differences between single and sequentially applied adhesive part regarding the quantitative evaluation. The test material showed a moderate grade of cytotoxicity. As a result, a statistically significant difference of the cytotoxicity between the self-etch and etch-and-rinse adhesives cannot be demonstrated regarding the qualitative evaluation and the reactivity index, but the differences between sequentially applied and single applied components can be proved.
Complete reosseointegration after treatment of periimplantitis was never published yet. This short scientific communication reports about results of a randomized controlled preclinical study. An electrolytic approach was compared to a classical modality (ablative, cotton pellets soaked with sodium chloride solution and H2O2. For electrolytic cleaning a complete reosseointegration was achieved in several cases serving as a proof of concept.
Objective: Pancreatic ductal adenocarcinoma (PDAC) still carries a dismal prognosis with an overall 5-year survival rate of 9%. Conventional combination chemotherapies are a clear advance in the treatment of PDAC; however, subtypes of the disease exist, which exhibit extensive resistance to such therapies. Genomic MYC amplifications represent a distinct subset of PDAC with an aggressive tumour biology. It is clear that hyperactivation of MYC generates dependencies that can be exploited therapeutically. The aim of the study was to find and to target MYC-associated dependencies.
Design: We analysed human PDAC gene expression datasets. Results were corroborated by the analysis of the small ubiquitin-like modifier (SUMO) pathway in a large PDAC cohort using immunohistochemistry. A SUMO inhibitor was used and characterised using human and murine two-dimensional, organoid and in vivo models of PDAC.
Results: We observed that MYC is connected to the SUMOylation machinery in PDAC. Components of the SUMO pathway characterise a PDAC subtype with a dismal prognosis and we provide evidence that hyperactivation of MYC is connected to an increased sensitivity to pharmacological SUMO inhibition.
Conclusion: SUMO inhibitor-based therapies should be further developed for an aggressive PDAC subtype.
Introduction: There is still an ongoing debate whether a transrectal ultrasound (TRUS) approach for prostate biopsies is associated with higher (infectious) complications rates compared to transperineal biopsies. This is especially of great interests in settings with elevated frequencies of multidrug resistant organisms (MDRO).
Materials and Methods: Between 01/2018 and 05/2019 230 patients underwent a TRUS-guided prostate biopsy at the department of Urology at University Hospital Frankfurt. Patients were followed up within the clinical routine that was not conducted earlier than 6 weeks after the biopsy. Among 230 biopsies, 180 patients took part in the follow-up. No patients were excluded. Patients were analyzed retrospectively regarding complications, infections and underlying infectious agents or needed interventions.
Results: Of all patients with follow up, 84 patients underwent a systematic biopsy (SB) and 96 a targeted biopsy (TB) after MRI of the prostate with additional SB. 74.8% of the patients were biopsy-naïve. The most frequent objective complications (classified by Clavien-Dindo) lasting longer than one day after biopsy were hematuria (17.9%, n = 32), hematospermia (13.9%, n = 25), rectal bleeding (2.8%, n = 5), and pain (2.2%, n = 4). Besides a known high MDRO prevalence in the Rhine-Main region, only one patient (0.6%) developed fever after biopsy. One patient each (0.6%) consulted a physician due to urinary retention, rectal bleeding or gross hematuria. There were no significant differences in complications seen between SB and SB + TB patients. The rate of patients who consulted a physician was significantly higher for patients with one or more prior biopsies compared to biopsy-naïve patients.
Conclusion: Complications after transrectal prostate biopsies are rare and often self-limiting. Infections were seen in <1% of all patients, regardless of an elevated local prevalence of MDROs. Severe complications (Clavien-Dindo ≥ IIIa) were only seen in 3 (1.7%) of the patients. Repeated biopsy is associated with higher complication rates in general.
Using an original dataset on professional networks of directors sitting on the boards of large US corporations, we examine how personal relationships are used by firms to improve job match quality in the high-skill segment of the labor market. Analyzing explicit social connection data between new hires and recruiters, we are able to test predictions of well established job referral models. We find that referred executive directors have a fifteen percent longer tenure than their non-referred counterparts. Referred executive directors also tend to be similar to their referrers on multiple dimensions, giving support to network homophily hypotheses.
Background: Prolonged grief disorder (PGD) will be newly included in the ICD-11, while a clinically similar diagnosis, persistent complex bereavement disorder (PCBD), has already been added to the DSM-5. Only few studies have evaluated these criteria-sets for prolonged grief.
Objective: The aim of this study was to evaluate the ICD-11 accessory symptom threshold and compare the diagnostic performance of the two criteria-sets in treatment-seeking bereaved persons.
Method: 113 grief treatment-seeking bereaved persons completed the Interview for Prolonged Grief-13. We used receiver operator characteristic analysis to determine an optimum ICD-11 accessory symptom threshold. We calculated diagnostic rates for PGD and PCBD and examined associations of PGD and PCBD caseness with concurrently assessed psychopathology and prolonged grief symptoms assessed one month later.
Results: An ICD-11 threshold of six accessory symptoms distinguished optimally between interview-diagnosed participants with and without prolonged grief. The prevalence of PGD (69%) was significantly higher than that of PCBD (48%) and of PGD with a 6-symptom threshold (47%). PGD caseness was associated with the relation to the deceased, 6-symptom threshold PGD and PCBD caseness with the time since loss. All criteria-sets were linked to concurrent prolonged grief, depression, and general mental distress. PCBD and 6-symptom threshold PGD but not PGD were associated with prolonged grief severity one month later.
Conclusions: The results support the validity of PGD and PCBD but, at the same time, they provide further support for differing prevalence rates. Using an empirically determined ICD-11 accessory symptom threshold could prevent the pathologisation of grief reactions.
CD8+ T cells are key players in immunity against intracellular infections and tumors. The main cytokine associated with these protective responses is interferon-γ (IFN-γ), whose production is known to be regulated at the transcriptional level during CD8+ T cell differentiation. Here we found that microRNAs constitute a posttranscriptional brake to IFN-γ expression by CD8+ T cells, since the genetic interference with the Dicer processing machinery resulted in the overproduction of IFN-γ by both thymic and peripheral CD8+ T cells. Using a gene reporter mouse for IFN-γ locus activity, we compared the microRNA repertoires associated with the presence or absence of IFN-γ expression. This allowed us to identify a set of candidates, including miR-181a and miR-451, which were functionally tested in overexpression experiments using synthetic mimics in peripheral CD8+ T cell cultures. We found that miR-181a limits IFN-γ production by suppressing the expression of the transcription factor Id2, which in turn promotes the Ifng expression program. Importantly, upon MuHV-4 challenge, miR-181a-deficient mice showed a more vigorous IFN-γ+ CD8+ T cell response and were able to control viral infection significantly more efficiently than control mice. These data collectively establish a novel role for miR-181a in regulating IFN-γ–mediated effector CD8+ T cell responses in vitro and in vivo.
Biologics have transformed the treatment of immune-mediated inflammatory diseases such as rheumatoid arthritis (RA) and inflammatory bowel disease (IBD). Biosimilars—biologic medicines with no clinically meaningful differences in safety or efficacy from licensed originators—can stimulate market competition and have the potential to expand patient access to biologics within the parameters of treatment recommendations. However, maximizing the benefits of biosimilars requires cooperation between multiple stakeholders. Regulators and developers should collaborate to ensure biosimilars reach patients rapidly without compromising stringent quality, safety, or efficacy standards. Pharmacoeconomic evaluations and payer policies should be updated following biosimilar market entry, minimizing the risk of imposing nonmedical barriers to biologic treatment. In RA, disparities between treatment guidelines and national reimbursement criteria could be addressed to ensure more uniform patient access to biologics and enable rheumatologists to effectively implement treat-to-target strategies. In IBD, the cost-effectiveness of biologic treatment earlier in the disease course is likely to improve when biosimilars are incorporated into pharmacoeconomic analyses. Patient understanding of biosimilars is crucial for treatment success and avoiding nocebo effects. Full understanding of biosimilars by physicians and carefully considered communication strategies can help support patients initiating or switching to biosimilars. Developers must operate efficiently to be sustainable, without undermining product quality, the reliability of the supply chain, or pharmacovigilance. Developers should also facilitate information sharing to meet the needs of other stakeholders. Such collaboration will help to ensure a sustainable future for both the biosimilar market and healthcare systems, supporting the availability of effective treatments for patients.